<SUBMISSION>
<ACCESSION-NUMBER>0001157523-09-000678
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20090129
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20090130
<DATE-OF-FILING-DATE-CHANGE>20090129
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>PRO PHARMACEUTICALS INC
<CIK>0001133416
<ASSIGNED-SIC>2834
<IRS-NUMBER>043562325
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31791
<FILM-NUMBER>09555805
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
<PHONE>6175590033
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a5883878.htm
<DESCRIPTION>PRO-PHARMACEUTICALS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2008 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">
      <font style="font-size: 18pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><br><font style="font-size: 18pt; font-family: Times New Roman"><b>SECURITIES
      AND EXCHANGE COMMISSION</b></font><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font><br><br><font style="font-size: 16pt; font-family: Times New Roman"><b>Form
      8-K</b></font><br><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Current
      Report</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Pursuant
      to Section 13 or 15(d) of</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>the
      Securities Exchange Act of 1934</b></font><br><br><br><font style="font-size: 10pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported): January 29, 2009</font><br><br>
    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; margin-bottom: 10.0px; font-family: Times New Roman; width: 100%">
      <tr>
        <td valign="top" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 14pt">PRO-PHARMACEUTICALS, INC.</font>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt">(Exact name of registrant as
            specified in its charter)</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <br>

    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; margin-bottom: 10.0px; font-family: Times New Roman; width: 100%">
      <tr>
        <td valign="bottom" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px; width: 33%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Nevada
          </p>
        </td>
        <td valign="bottom" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 34%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            000-32877
          </p>
        </td>
        <td valign="bottom" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 33%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            04-3562325
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 33%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(State
            or other jurisdiction of</font><br><font style="font-size: 10pt; font-family: Times New Roman">
            incorporation or organization)</font>
          </p>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 34%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Commission
            File Number)</font>
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 33%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(I.R.S.
            Employer</font>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">Identification
            No.)</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; margin-bottom: 10.0px; font-family: Times New Roman; width: 100%">
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt">7 Wells Avenue, Newton, Massachusetts</font>
          </p>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt">02459</font>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Address
            of principal executive offices)</font>
          </p>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Zip
            code)</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      (Registrant&#8217;s telephone number, including area code): (617) 559-0033
    </p>
    <p style="text-align: center">

    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; margin-bottom: 10.0px; font-family: Times New Roman; width: 100%">
      <tr>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px">
          (Former name or former address, if changed since last report)
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <br>

    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Item 8.01 Other Events.</b>
    </p>
    <p>
      On January 29, 2009, Pro-Pharmaceuticals, Inc. issued a news release
      announcing that the U.S. Food &amp; Drug Administration (FDA), in a pre-New
      Drug Application (NDA) meeting held last December, indicated the Company
      will be required to conduct a Phase lll trial to demonstrate superiority
      to the best standard of care for late stage colorectal cancer
      patients.&#160;&#160;&#160;As part of the Phase lll trial, the Company plans to open
      the study to conduct a pharmacokinetic (PK) analysis of approximately 60
      patients, which may allow the Company to file for an NDA for DAVANAT<sup>&#174;</sup>
      as an adjuvant when administered with 5-Fluorouracil (5-FU), an FDA
      approved chemotherapy.&#160;&#160;The Company expects to enroll approximately 300
      patients in the Phase lll trial.&#160;&#160;Adjuvants are pharmacological or
      immunological agents that modify the effect of other agents, such as
      drugs or vaccines.
    </p>
    <p>
      A copy of Pro-Pharmaceuticals news release is attached as Exhibit 99.1
      hereto and incorporated by reference herein.
    </p>
    <p style="text-align: left">
      <b>Item 9.01 Financial Statements and Exhibits.</b>
    </p>
    <p style="text-align: left; margin-left: 30.0px">
      <b>(c)&#160;&#160;&#160;Exhibits</b>
    </p>
    <p style="text-align: justify">
      99.1&#160;&#160;News release of Pro-Pharmaceuticals, Inc. dated January 29, 2009.
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURE</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned thereunto duly authorized.</font>
    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; margin-bottom: 10.0px; font-family: Times New Roman; width: 100%">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px" colspan="2">
          <p style="margin-bottom: 0px; margin-top: 0px">
            PRO-PHARMACEUTICALS, INC.
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px" colspan="2">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td colspan="2">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; padding-bottom: 2.0px; width: 5%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; padding-bottom: 2.0px; width: 45%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; padding-bottom: 2.0px; width: 3%">
          By:
        </td>
        <td valign="top" style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 0.0px; width: 47%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Anthony D. Squeglia
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 47%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Anthony D. Squeglia
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 47%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 47%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 5%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Date:
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 45%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            January 29, 2009
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 47%">

        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a5883878ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2008 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>FDA
      Provides Clear Path to NDA Submission for Pro-Pharmaceuticals&#8217; DAVANAT</b></font><b><sup><font style="font-size: 12pt; font-family: Times New Roman">&#174;</font></sup></b>
    </p>
    <p>
      NEWTON, Mass.--(BUSINESS WIRE)--January 29, 2009--<b>Pro-Pharmaceuticals,
      Inc. (OTCBB: PRWP)</b> today announced that the U.S. Food &amp; Drug
      Administration (FDA), in a pre-New Drug Application (NDA) meeting held
      last December, indicated the Company will be required to conduct a Phase
      III trial to demonstrate superiority to the best standard of care for
      late stage colorectal cancer patients. As part of the Phase III trial,
      the Company plans to open the study to conduct a pharmacokinetic (PK)
      analysis of approximately 60 patients, which may allow the Company to
      file for an NDA for DAVANAT<sup>&#174;</sup> as an adjuvant when
      administered with 5-Fluorouracil (5-FU), an FDA approved chemotherapy.
      The Company expects to enroll approximately 300 patients in the Phase
      III trial. Adjuvants are pharmacological or immunological agents that
      modify the effect of other agents, such as drugs or vaccines.
    </p>
    <p>
      The results of the Company&#8217;s completed Phase I trial for late stage
      cancer patients indicate that DAVANAT<sup>&#174; </sup>may improve the
      PK profile of 5-FU in patients by keeping the chemotherapy in the
      bloodstream longer with no increase in toxicity.
    </p>
    <p>
      &#8220;Our strategy is to file an NDA to commercialize DAVANAT<sup>&#174; </sup>as
      quickly as possible by demonstrating enhanced PK in combination with
      5-FU. Our goal is to complete the Phase III trial and to demonstrate
      superiority to the best standard of care for late stage colorectal
      cancer patients,&#8221; said David Platt, Ph.D., Chief Executive Officer,
      Pro-Pharmaceuticals, Inc. &#8220;To date, DAVANAT has been administered to
      approximately 100 cancer patients. In a Phase II trial for end-stage
      colorectal cancer patients, DAVANAT<sup>&#174; </sup>extended median
      survival to 6.7 months with significantly reduced side effects, as
      compared with 4.6 months for the best standard of care.&#8221;
    </p>
    <p>
      The Company plans to file a Special Protocol Assessment (SPA) for the
      Phase III trial. The benefit of a successful SPA is that the FDA agrees
      that an uncompleted Phase III trial's design, clinical endpoints, and
      statistical analyses are acceptable for FDA approval. An SPA is a
      request for feedback from the FDA that allows a company to receive
      official evaluation and guidance on the design of pivotal trial
      protocols.
    </p>
    <p>
      The Company is using DAVANAT<sup>&#174;</sup>, a galactomannan, to
      obtain more timely and efficient marketing approval of new formulations
      of previously approved therapeutics which incorporate the Company&#8217;s
      proprietary drug by means of the Section 505 (b)(2) regulatory pathway.
      Section 505 (b)(2) allows the FDA to approve a drug on the basis of data
      in the scientific literature or data previously cited by the FDA as the
      basis for the approval of related drugs. The FDA has approved
      galactomannans for other uses, such as oral or topical delivery. The
      Company is seeking approval for co-administration of DAVANAT<sup>&#174; </sup>with
      5-FU for intravenous injection for the treatment of advanced colorectal
      cancer.
    </p>
    <p>
      <b>About DAVANAT<sup>&#174;</sup></b>
    </p>
    <p>
      DAVANAT<sup>&#174;</sup>, a new chemical entity, is a proprietary
      carbohydrate compound that is administered with chemotherapies and
      biologics to treat cancer. DAVANAT<sup>&#174;</sup>'s mechanism of
      action is based on binding to lectins. DAVANAT<sup>&#174;<b> </b></sup>targets
      specific lectin receptors (Galectins) on cancer cells. Current research
      indicates that Galectins affect cell development and play important
      roles in cancer, including tumor cell survival, angiogenesis and tumor
      metastasis.
    </p>
    <div style="text-indent: 0pt; margin-right: 0pt; margin-bottom: 10pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Pro-Pharmaceuticals, Inc. &#8211; Advancing Drugs Through Glycoscience<sup>&#174;</sup></b>
    </p>
    <p>
      Pro-Pharmaceuticals is engaged in the discovery, development, and
      commercialization of carbohydrate-based therapeutics for advanced
      treatment of cancer, liver, microbial, and inflammatory diseases.
      Initially, the product pipeline is focused on developing targeted
      therapeutics to treat cancer. The Company&#8217;s technology also is being
      developed to explore the treatment of liver and kidney fibrosis. The
      Company is headquartered in Newton, Mass. Additional information is
      available at <u>www.pro-pharmaceuticals.com</u>.
    </p>
    <p>
      <b>FORWARD LOOKING STATEMENTS:</b> Any statements in this news release
      about future expectations, plans and prospects for the Company,
      including without limitation, statements containing the words believes,
      anticipates, plans, expects, and similar expressions, constitute
      forward-looking statements as defined in the &quot;safe harbor&quot; provisions of
      the Private Securities Litigation Reform Act of 1995. These
      forward-looking statements are based on management's current
      expectations and are subject to a number of factors and uncertainties,
      including results of our clinical trials, FDA response to a Special
      Protocol Assessment or submission of a Section 505(b)(2) New Drug
      Application, which could cause actual results to differ materially from
      those, described in such statements. We caution investors that actual
      results or business conditions may differ materially from those
      projected or suggested in forward-looking statements. More information
      about those risks and uncertainties is contained in the Company's most
      recent quarterly or annual report and other reports filed with the
      Securities and Exchange Commission. While the Company anticipates that
      subsequent events may cause the Company's views to change, the Company
      disclaims any obligation to update such forward-looking statements.
    </p>
    <p>
      DAVANAT and Advancing Drugs Through Glycoscience are registered
      trademarks of Pro-Pharmaceuticals.
    </p>
    <p>
      CONTACT:<br>Pro-Pharmaceuticals, Inc.<br>Anthony D. Squeglia,
      617-559-0033<br><u>squeglia@pro-pharmaceuticals.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SUBMISSION>
